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Background: Offspring of pregnancy complicated with gestational diabetes (GDM) are at high risk for metabolic
diseases. The mechanisms behind the association of intrauterine exposure to GDM and high risk of health problems
in later life remain largely unknown. The aim of this study was to clarify the alteration in methylation levels at
differentially methylated regions (DMRs) of GNAS and IGF2 in fetuses of GDM women and to explore the possible
mechanisms linking maternal GDM with high risk of metabolic diseases in later life of GDM offspring.
Methods: Lymphocytes were isolated from umbilical cord blood of infants born to 87 women with GDM and 81
women with normal pregnancy. Genomic DNA was extracted and DNA methylation levels of GNAS and IGF2 DMRs
were determined by Massarray quantitative methylation analysis.
Results: The methylation levels were detected in 7 CpG sites of GNAS DMRs and 6 sites of IGF2 DMRs. Methylation levels
were significantly higher at sites 4, 5 and 7 of GNAS DMR in GDM compared to normal pregnancy (P = 0.007, 0.008 and
0.008, respectively). The methylation level at site 4 of GNAS was significantly correlated with the presence of GDM
(P = 0.003), the methylation levels at site 5 and 7 were significantly correlated with the presence of GDM (P = 0.002 for
both) and gestational age (P = 0.027 for both). There was no significant difference in any sites of IGF2 DMR
(P > 0.05 for all).
Conclusions: We concluded maternal GDM-induced hypermethylation at GNAS DMR and this condition may be
among the mechanisms associating maternal GDM with increased risk of metabolic diseases in later life of offspring.
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Gestational diabetes mellitus (GDM), defined as any de-
gree of glucose intolerance with onset or first recogni-
tion during pregnancy, affects 2 - 12% of all pregnancies
[1,2]. GDM is associated with adverse pregnancy out-
comes, including macrosomia and subsequently birth
trauma, and fetal hypoglycemia, hypocalcaemia, respira-
tory distress, and even stillbirth, whereas treatments of
GDM improve pregnancy outcomes [3,4]. GDM poses
life-long risk to the offspring, such as increased birth* Correspondence: superliuyun@gmail.com; mydong.cn@hotmail.com
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unless otherwise stated.weight, higher BMI at age of 6–24 and incidence of ado-
lescent obesity compared to controls [5-7]. Numeral
studies have shown an increase in metabolic syndrome
in offspring of GDM pregnancies [8]. The prevalence of
impaired glucose tolerance is higher in the offspring of
mothers with gestational and pre-gestational diabetes than
those of background population [9-12]. Animal studies
revealed metabolic imprinting of intrauterine diabetic en-
vironment can be transmitted across generations [13]. Al-
though studies in human and animal have demonstrated
the association of GDM and risk of obesity, diabetes and
metabolic diseases in offspring of GDM pregnancies, the
mechanisms behind remain elusive.
Epigenetic modification might be among the mechanisms
underlying this association [14]. The persistent epigenetictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment may be among the mechanisms contributing to
the association between maternal GDM and health
problems in later life of offspring. Imprinted genes play
important roles in embryonic growth and development
and epigenetic disruption due to adversity in early life
may be associated with susceptibility to metabolic dis-
eases [15]. GDM induces differential methylation of
genes in fetal DNA from offspring born to GDM
mothers. Ruchat et al. [16] reported that GDM has epi-
genetic effects on genes preferentially involved in the
metabolic diseases pathway and proposed that DNA
methylation is involved in fetal metabolic and develop-
mental programming. Differential methylation of fetal
MEST and ABCA1 was also observed [17,18].
Insulin-like growth factor 2 (IGF2) is a paternally
expressed gene widely expressed during prenatal devel-
opment and its activity is regulated by genomic imprint-
ing. Imprinted expression of IGF2 is partially maintained
through the differentially methylated region (DMR) lo-
cated between exon 2 and 3, the disrupted methylation
of which is associated with congenital growth disorders
[19,20]. Guanine nucleotide binding protein alpha sub-
unit (GNAS) is an imprinted gene with a highly complex
imprinted expression pattern, which gives rise to mater-
nally, paternally, and biallelically expressed transcripts
[21,22]. The imprinted expression of GNAS is controlled
by the DMR in exon 1A [23]. The methylation at differ-
entially methylated region (DMR) of imprinted genes is
established before gastrulation and is very sensitive to
early developmental environment, but can be relatively
stable throughout the life of individual [21,22]. The in-
vestigations in subjects conceived during Dutch famine
winter revealed that the exposure to prenatal famine re-
sulted in the persistent alteration in DNA methylation of
imprinted genes including GNAS and IGF2 [24,25].
Small-for-gestational age (SGA) and preeclampsia, con-
ditions characterized by poor nutrient supply to fetus,
induces hypomethylation at IGF2 and GNAS DMRs and
altered methylation at DMRs of imprinted genes may
subsequently contribute to the development of meta-
bolic diseases in later life [22,26-28]. However, the effect
of GDM, a condition apposite to SGA and preeclampsia,
on the methylation at DMRs of IGF2 and GNAS of fetus
has not been described yet.
In addition, although both of GNAS and IGF2 gene
are associated with obesity [29,30] and hypertension
[31-34], currently there is no evidence if GDM modifies
epigenetic imprints of GNAS and IGF2 of fetus, or,
GNAS and IGF2 are possibly involved in the induction
of high risk of GDM-related metabolic diseases in adult-
hood. Therefore, we determined fetal methylation levels
at GNAS and IGF2 DMRs of GDM and normal preg-




Eighty-seven women of GDM and 81 normal pregnant
women were recruited in Women’s Hospital, School of
Medicine, Zhejiang University, Shaoxing Women and
Children’s Hospital, Ningbo Women and Children’s
Hospital, Huzhou Maternity and Child Care Hospital
and Jiaxing Maternity and Child Care Hospital.
Pregnancy was diagnosed upon positive human chori-
onic gonadotropin (hCG) test after missed menstruation.
Gestational age was calculated by menstrual dating. Ultra-
sound was performed to confirm pregnancy and gesta-
tional age. GDM was diagnosed according to the criteria
recommended by International Association of Diabetes
and Pregnancy Study Groups (IADPSG) [35]. All GDM
women controlled their glycemia with dietary control and
physical activity. Exclusion criteria were multiple gestation,
diabetes mellitus, chronic hypertension, infectious diseases
recognized in pregnancy, premature rupture of membrane,
active labor, polyhydramnios and signs of other concurrent
medical complication. The control women had no sign of
gestational complications and fetal distress and gave birth
to healthy neonates of appropriate size for gestational age.
Clinical data and demographic data were collected ac-
cording to the medical records. The approval of the current
study was obtained from Institutional Ethical commit-
tee of Women’s Hospital, School of Medicine, Zhejiang
University, and all the participants provided their in-
formed consents.
DNA methylation analysis
Umbilical cord blood samples were collected in Ethylene
Diamine Tetraacetic Acid (EDTA)-treated tubes at delivery.
Lymphocytes of infants were isolated and stored at -80C
until use. Total DNA was isolated from lymphocytes using
buffer ATL, proteinase K, and RNase A (Qiagen, Inc.,
Valencia, CA) followed by phenol–chloroform extrac-
tion and ethanol precipitation. Bisulfite conversion of
DNA was carried out using the Epitect Bisulfite Kit
(Qiagen Inc., Valencia, CA).
Quantitative methylation analysis of DNA was per-
formed using MassARRAY EpiTYPER assays (Sequenom,
San Diego, CA) according to the protocol recommended
by the manufacturer. Methylation of all CpG sites at the
IGF2 DMR in Chr11: 2169100–2169551, and GNAS DMR
in Chr 20: 57,415,713-57,416,072 was measured, quantita-
tive methylation of each CpG unit was calculated follow-
ing the method described in our previous study [28].
Seven CpG sites in the GNAS DMR and six CpG sites in
the IGF2 DMR were qualified for reliable detection based
on CpG unit mass quality evaluated by EpiTYPER and
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sites in the DMRs were discarded as they are either non-
quantifiable or ambiguous CpG sites. Positions of each
CpG site was stated in our previous study [28].Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate the
distribution of data. Continuous data were presented in
mean and standard deviation (SD) and compared with
Student t-tests while categorical data were evaluated with
Chi-square test. Multiple variant regression analysis was
used to evaluate the relationship of methylation level with
the presence of GDM, birth weight, maternal age, gesta-
tional age at delivery and fetal gender. SPSS statistical
package (Statistical Analysis System, Chicago, IL) was used
for the statistic analysis. Values of P < 0.05 were consid-
ered to be statistically significant.Results
As shown in Table 1, there were significant differences in
maternal age, gestational age at delivery and neonatal birth
weight between GDM and normal pregnancy (P < 0.001
for all). Maternal age was greater, gestational age was
shorter and birth weight was heavier in GDM group com-
pared to normal pregnancy. There was no significant dif-
ference in fetal gender (P = 0.504).
The methylation levels were detected in 7 CpG sites of
GNAS DMRs and 6 sites of IGF2 DMRs (Figures 1 and 2).
Methylation levels at sites 4, 5 and 7 of GNAS DMR were
significantly higher in GDM compared to normal preg-
nancy (P = 0.007, 0.008 and 0.008, respectively), but there
were no significant differences in methylation levels at
sites 2, 8, 9 and 12 (P = 0.254, 0.122, 0.254 and 0.077, re-
spectively). The methylation level of CpG site 4, 5 and 7 of
GNAS DMR were significantly correlated with the pres-
ence of GDM (P = 0.003; P = 0.002 for site 5 and 7), fur-




Maternal age (y) 28.6 ± 3.4
Gestational age at delivery (w) 38.70 ± 1.37
Infant characteristics




methylation level at GNAS DMR 0.51 ± 0.056
methylation level at IGF2 DMR 0.46 ± 0.043significantly correlated with gestational age (P = 0.027 for
both).
There were no significant differences in methylation
levels at CpG sites 3, 4, 6, 7, 9 and 10 of IGF2 DMR be-
tween GDM and normal pregnancy (P = 0.792, 0.840,
0.455, 0.784, 0.845 and 0.214, respectively). When it
comes to the mean methylation levels of all those CpGs
sites at the GNAS and IGF2 DMRs, there were not sig-
nificantly different between GDM and normal pregnancy
(P = 0.271 and 0.689, respectively)(Table 1).
Discussion
In the current investigation, increased methylation in
CpGs sites of GNAS DMR was observed in fetuses of
GDM women compared to control. Our data imply that
increased methylation at GNAS DMR may be among the
mechanisms linking maternal GDM with high risk of
metabolic diseases in later life of fetuses. Whereas, un-
changed methylation at IGF2 DMR indicate IGF2 is not
vulnerable to GDM-induced intrauterine environment.
GNAS, the gene encoding G protein alpha (GSα), is
imprinted in a tissue-specific manner. There are three
DMRs located from upstream to downstream of the
GSα promoter: the first one is in the NESP55 promoter
region, the second is in the NESPAS/GNASXL promoter
region and the third one is located in the GNAS exon
1A region. The Exon 1A DMR controlls the imprinted
expression of GNAS [20]. GSα is equally expressed from
both alleles in most tissues, but is expressed primarily
from the maternal allele in certain hormone-target tis-
sues, such as thyroid and pituitary et al. [36,37]. The
DMR analyzed in our study, which is located in the exon
1A DMR, is necessary for tissue-specific imprinting of
GSα [23]. GSα plays an important role in energy metabol-
ism and the development of obesity [29]. The mutations
of GNAS which disrupt GSα expression or function cause
Albright hereditary osteodystrophy (AHO), a congenital
syndrome which is characterized by obesity, short statured IGF2 DMRs
Gestational diabetes Significance
87
30.61 ± 3.8 <0.001
37.56 ± 1.86 <0.001
3559 ± 592 <0.001
Male:45 0.504
Female:42
0.52 ± 0.059 0.271
0.46 ± 0.048 0.689
Figure 1 Site-specific methylation levels at GNAS DMR in fetuses of normal pregnancy and gestational diabetes (GDM). There were
significant differences in methylation levels at site 4, 5 and 7 between fetuses of normal pregnancy and GDM (P = 0.007, 0.008 and 0.008,
respectively). The differences were not significant in the methylation levels at site 2, 8, 9 and 12 (P = 0.254, 0.122, 0.254 and 0.077, respectively).
Figure 2 Site-specific methylation levels at IGF2 DMR in fetuses of normal pregnancy and gestational diabetes (GDM). There were no
significant differences in methylation levels at sites 3, 4, 6, 7, 9 and 10 of IGF2 DMR between GDM and normal pregnancy (P = 0.792, 0.840, 0.455,
0.784, 0.845 and 0.214, respectively)
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the maternal allele develop resistance to hormones includ-
ing parathyroid hormone, thyrotropin, growth hormone-
releasing hormone and gonadotropins. In this condition,
obesity occurs very early (usually within the first year) and
tends to be severe in early childhood. In addition, animal
study showed that GNAS knock-out mice with an inser-
tion mutation on maternal allele develops obesity with in-
creased serum leptin levels and lipid accumulation [38].
It was reported that prenatal exposure to adverse en-
vironment, such as disturbed intrauterine environment,
dysregulates the fetal epigenome, with potential conse-
quences for subsequent developmental disorders and
disease over the life course [39]. However, no literature
describing the effects of GDM on fetal GNAS was avail-
able yet. Herein, we reported for the first time the in-
creased methylation at GNAS DMR in GDM fetuses
compared to control, indicating methylation of GNAS
DMR is sensitive to GDM-induced intrauterine environ-
ment. Regression analysis excluded the confounder effect
of maternal age and birth weight on methylation in
GNAS DMR but we could neither exclude the possible
effect of gestational age nor determine the causal rela-
tionship between GDM and hypermethylation of GNAS
DMR. As disruption in the imprinted expression of GSα
leads to the development of obesity, our data also pro-
vide a clue to mechanisms linking maternal GDM with
risk to chronic diseases for infants in adulthood, such as
obesity. Further evidence linking increased methylation
at GNAS DMR with the expression or function of GSα
in a tissue-specific manner would enhance our insight
into the role of increased methylation at GNAS in the
development of obesity. Animal models or cell lines are
needed for these purposes.
In this paper, we also analyzed differences of methyla-
tion levels in the IGF2 DMR in fetuses of GDM women
comparing to control. The imprinting of IGF2 is main-
tained by two regulatory DMRs located close to exon 3
(also referred to IGF2 DMR or DMR0) and upstream of
neighboring maternally expressed H19 (referred to H19
DMR). Multiple CpG sites in the IGF2 DMR were found
to be associated with higher newborn birth and placenta
weight, while no significant association was observed in
the H19 DMR [40]. In addition, hypomethylation of
IGF2 DMR was also associated with elevated plasma
IGF2 protein concentrations and higher birth weight in
infant born to obesity women while patterns of associ-
ation were not apparent at the H19 DMR [41]. Another
study revealed that the methylation levels of IGF2 DMR
were affected by folic acid intake before or during preg-
nancy and depression in pregnancy [42]. Taken together
with our previous study reported significant lower
methylation in offspring of preeclampsia than normal
pregnancy [28], it indicates that the methylation of IGF2DMR could be a better biomarker than H19 DMR to
evaluated the effect of environmental exposure in early
development. Therefore, we investigated the association
between methylation levels of the IGF2 DMR located be-
tween the exon 2 and 3 of IGF2 with intrauterine expos-
ure to GDM. However, our study failed to find significant
methylation changes of IGF2 DMR between infants born
to GDM mother and normal control. The lack of associ-
ation between the IGF2 DMR methylation profile and
GDM in our study indicated that the IGF2 DMR may not
be vulnerable to GDM-induced intrauterine environment.
However, animal studies revealed hypermethylation at
IGF in diabetic offspring. Shao et al. reported that the
methylation level of the H19–Igf2 imprint control region
was 19.1% higher while the body weight was 26.5% lower
in pups born to diabetic mice compared to controls [43].
Ding et al. observed hypermethylation at H19-Igf2 DMRs
and reduced expression of IGF2 in pancreatic islets iso-
lated from pups of diabetic mice [44]. In addition, mur-
ine diabetes influenced placental expression of Igf2 [45].
Murine diabetes is induced by intraperitoneal injection
of streptozotocin and is characterized by poor maternal
nutritional condition and low pup weight. The birth
weight is usually higher in GDM than control as demon-
strated in the current investigation. The differences in
maternal disorder (GDM versus streptozotocin-induced
diabetes), maternal nutrition condition (good versus poor),
species (human versus murine) and birth weight are the
possible factors responsible for the different methylation
in IGF2MDR observed in humans and mice.
Conclusion
In summary, we reported that GDM induced signifi-
cantly increased methylation levels at fetal GNAS DMR
compared with control, suggesting that hypermethyla-
tion at GNAS DMR may be among the mechanisms
linking maternal GDM with high risk for chronic dis-
eases in later life of offspring. Further investigation is
needed to clarify the exact role of GNAS in the develop-
ment of obesity and hypertension and to identify pos-
sible target point for the reduction of the risk for
metabolic diseases in later life of GDM fetuses.
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